Circana Aggregated Retailer Data Integrated in the LiveRamp Clean Room, Accelerating Advertiser Ability to Boost Performance Outcomes
Circana, which tracks $5.8 trillion in consumer sales, offers the most comprehensive and verified consumer sales data in the industry. This data is fueled by unparalleled retailer membership loyalty card data for the U.S. CPG sector, providing noticeably greater sales coverage compared to other purchase-based data providers. Additionally, Circana's Complete Consumer™ receipt panel, representing approximately 200,000 static households, delivers robust insights across general merchandise industries, such as luxury beauty, consumer technology, apparel, foodservice, and others.
With this integration, advertisers gain seamless access to Circana's aggregated, multi-outlet retailer transaction data, providing granular, omnichannel insights that can power real-time data-driven decisions and help brands win share. Marketers can now:
Build smarter profiles with a deeper understanding of customer purchase behavior both within and across product categories, powered by Circana's premium data assets.
Define and activate high-value audiences using Circana's known, aggregated multi-retailer purchase data that reflects actual consumer buying patterns.
Distribute campaigns at scale across over 150 destinations via LiveRamp's powerful data collaboration network.
Access standardized insights with minimal cost or complexity.
Circana and LiveRamp remain focused on helping advertisers deliver on outcomes that prove ROI. As a further expansion to this solution, advertisers will be able to enrich their first-party data with Circana's purchase-based insights directly within the LiveRamp Clean Room, unlocking deeper analytics, more powerful modeling, and high-impact audience activation. They can also measure campaign performance in near real time, using conversion attribution to refine tactics and optimize marketing efforts to focus on those levers that drive measurable performance gains.
'Circana is committed to delivering the data and solutions our clients need to make confident, data-driven decisions that maximize sales outcomes,' said Dave Slowik, executive vice president of Global Media at Circana. 'This expanded partnership with LiveRamp reflects our shared mission to address evolving advertiser challenges with innovative, trusted solutions that fuel measurable results.'
'LiveRamp and Circana's growing partnership continues to enhance advertisers' ability to plan, target, activate, and measure effectively,' said Vihan Sharma, chief revenue officer at LiveRamp. 'Integrating clean room intelligence and standardization empowers data to become more connected, measurable, and adaptive, enabling more actionable insights and faster time-to-value.'
About CircanaCircana is a leader in providing technology, AI, and data to fast-moving consumer packaged goods companies, durables manufacturers, and retailers seeking to optimize their businesses. Circana's predictive analytics and technology empower clients to measure their market share, understand the underlying consumer behavior driving it, and accelerate their growth. Circana's Liquid Data® technology platform is powered by an expansive, high-quality data set and intelligent algorithms trained on six decades of domain expertise. With Circana, clients can take immediate action to future-proof and evolve their growth strategies amid an increasingly complex, fast-paced, and ever-changing economy. Learn more at circana.com.
Media ContactShelley HughesEmail: shelley.hughes@circana.com312-731-1782
CONTACT: Shelley Hughes Circana +1 312-731-1782 Shelley.Hughes@Circana.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections. The company recently secured additional Medicare reimbursement for its aprevo personalized interbody implants for cervical fusion procedures, effective October 1, enhancing its financial outlook. This favorable reimbursement, granted through the Centers for Medicare & Medicaid Services' (CMS) New Technology Add-On Payment (NTAP) program in the Hospital Inpatient Prospective Payment Systems (IPPS) Final Rule for fiscal year 2026, means cervical fusion procedures using aprevo devices will be eligible for an additional $21,125 beyond standard Medicare Severity-Diagnosis-Related Groups (MS-DRGs) for qualifying inpatient benefit extends to private payors as well, utilizing unique ICD-10-PCS procedure codes. Carlsmed, which priced its initial public offering of 6.7 million shares at $15 per share in July, focuses on AI-enabled personalized spine surgery solutions. Its aprevo cervical system, having received FDA Breakthrough Device designation, is anticipated for a U.S. commercial launch in of America Securities (BofA) has initiated coverage on Carlsmed with a Buy rating and a price forecast of $16, recognizing the company's potential to establish a new standard of care in spine fusion. BofA analyst Travis Steed highlighted Carlsmed's differentiated technology and robust outlook, assigning a premium valuation of 5x 2026 estimated revenue. This premium, higher than recent medtech IPOs and other spine companies, is justified by Carlsmed's projected high revenue growth and strong gross margin profile. BofA conservatively forecasts Carlsmed will add around 20-25 new surgeons each quarter through 2027, indicating a steady increase in adoption. Carlsmed forecasts impressive top-line growth: 66% in 2025 and an annual 40-45% through 2028. Its asset-light business model is expected to support profitability, with gross margins in the mid-70s and capital expenditures at just 1% of sales, significantly lower than the approximately 10% for traditional spine peers. BofA estimates the total spine market at roughly $1.4 billion, with a compound annual growth rate (CAGR) of approximately 1.5%. In the first quarter of 2025, the global spine market (including biologics) saw 2.6% organic growth, driven by a 4.1% increase in the U.S. market. Despite the market being largely commoditized and dominated by major players like Medtronic Plc (NYSE:MDT), Globus Medical Inc (NYSE:GMED), Alphatec Holdings Inc. (NASDAQ:ATEC), Johnson and Johnson (NYSE:JNJ), and Orthofix Medical Inc. (NYSE:OFIX) (who collectively hold about 70% of the market), spine surgeons notably favor new technology. The remaining 30% of the market is split among many smaller companies, creating an opportunity for new market entrants with disruptive technology like Carlsmed's to gain traction. BofA sees significant market share capture potential for Carlsmed, with analyst Steed estimating total revenue of $133 million in 2028, representing only about 1% of the total U.S. spine market. Price Action: CARL stock is trading higher by 0.88% to $13.70 at last check Monday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Earnings Beat and Acquisitions Strengthen Rocket Companies Progress
Rocket Companies, Inc. (NYSE:RKT) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company surpassed Q2 expectations and has bolstered expectations for its Redfin acquisition and pending COOP transaction. A businessperson using a laptop to review the details of a mortgage loan for a client. Rocket Companies, Inc. (NYSE:RKT) is a leading fintech platform delivering mortgage lending, real estate brokerage, personal finance, and homeownership solutions. The Michigan-based company's ecosystem includes Rocket Mortgage, Rocket Homes, Rocket Close, and Rocket Money. Its business model involves leveraging AI to streamline the homebuying and financial management experience. On July 31, 2025, the company reported achieving an EPS of $0.04 that surpassed the analysts' expectations of $0.03 in its Q2 earnings results. Additionally, Rocket Companies, Inc. (NYSE:RKT)'s revenue reached $1.36 billion, exceeding the projected $1.28 billion, further garnering positive attention from investors. In addition to this, Rocket Companies, Inc. (NYSE:RKT) is anticipated to close the COOP transaction in the fourth quarter of 2025, thus eliminating elevated transaction-related expenses that negatively impacted the company's second-half 2025 earnings. Also, the acquisition of Redfin, completed on July 1, 2025, brought a positive outlook to the company as the combination of the most-visited real estate brokerage website and the U.S.'s largest mortgage lender is expected to improve efficacy. With a short float of 58.38%, Rocket Companies, Inc. (NYSE:RKT) potentially has extreme short interest. However, the stock attracts investor interest as it is subject to a dramatic squeeze in positive momentum. While we acknowledge the potential of RKT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Evercore ISI and Jefferies Maintain ‘Buy' Ratings on EQT Corporation (EQT)
EQT Corporation (NYSE:EQT) is included in our list of the . An aerial view of an oil rig in the Texas Gulf Coast with people working on it, emphasizing the company's oil & gas production interests. On July 27, 2025, Piper Sandler maintained its 'Neutral' rating on EQT Corporation (NYSE:EQT), raising its price target from $48 to $49. The price revision is attributed to a boost in the company's positioning, driven by Appalachia's long-term gas demand. New gas supply contracts and infrastructure investments will contribute $250 million in free cash flow by FY2029, the analyst noted. This inflow will be preceded by $1 billion in upfront costs. Meanwhile, Evercore ISI reaffirmed its 'Buy' rating on EQT Corporation (NYSE:EQT) with a $60 target on July 31. Additionally, Jefferies also maintained its 'Buy' rating with a $70 target on August 2. Despite the short-term market pressures from strong domestic supply and seasonal storage builds, these targets highlight the company's long-term growth outlook. Operating across the Appalachian Basin, EQT Corporation (NYSE:EQT) is a leading U.S. natural gas producer. It is included in our list of the most undervalued value stocks to buy. While we acknowledge the potential of EQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
